Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
BMC Cancer|November 8, 2024
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocolCassandra White, Hannah Wardill, Christine Paul, et al.
BMJ Open|May 2, 2025
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumoursTimothy Price, Iwona Lugowska, Sant P Chawla, et al.
BMC Cancer|August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Clinical Colorectal Cancer|January 8, 2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)Matthew E Burge, David Espinoza, Katrin Marie Sjoquist, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2025
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 studyAlberto Sobrero, Arvind Dasari, Jeneth Aquino, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized TherapyVignesh Narasimhan, Josephine A Wright, Michael Churchill, et al.
Nature Medicine|October 20, 2025
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trialJeanne Tie, Yuxuan Wang, Jonathan M Loree, et al.
Pageof 13